Source comparison
Tesamorelin for Visceral Fat Reduction Research: Study Design Comparison
NEJM 2010 (pooled) 806 HIV+ with lipohypertrophy 26 weeks 15.2% −0.8% Established selective VAT reduction without corresponding SAT loss in HIV population Diabetes Care 2024 218 metabolic syndrome 17.4% −1.2% VAT reduction did not improve HbA1c without dietary
This comparison does not assign a generated winner or score.
- NEJM 2010 (pooled)
- 806 HIV+ with lipohypertrophy
- 26 weeks
- 15.2%
- −0.8%
- Established selective VAT reduction without corresponding SAT loss in HIV population
- Diabetes Care 2024
- 218 metabolic syndrome
- 17.4%
- −1.2%
- VAT reduction did not improve HbA1c without dietary intervention. Isolated adipose effect
- Lancet 2025
- 412 adults, 2-year follow-up
- 104 weeks
- 18.1% sustained
- −1.5%
- 28% relative risk reduction in MACE. First cardiovascular outcome data
- Obesity Research 2023
- 156 post-menopausal women
- 52 weeks
- 16.8%
- +0.3%
- VAT reduction plateaued at month nine; lean mass increased 2.1kg